YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* InMed Pharmaceuticals (INM [https://seekingalpha.com/symbol/INM]) said [https://seekingalpha.com/pr/20657049-inmed-pharmaceuticals-receives-nasdaq-notification-regarding-minimum-shareholders-equity] on Friday it received a Nasdaq notice…
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement to leading healthca…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of the…
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to…
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 20…
InMed Pharmaceuticals (INM) shares ripped higher on May 19 as the company announced an all-stock merger with migraine drug developer Mentari Therapeutics. The combined company will trade on Nasdaq under a new ticker symbol, with INM shareh…
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 20…
BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (Nasdaq – INM) fo…
medical research glove ©Shutterstock The merger shifts InMed toward migraine prevention therapies while a large private financing is expected to fund operations through key clinical milestones. Key Investor Takeaways InMed Pharmaceuticals…
[M&A Mergers And Acquisitions] narvo vexar Canadian pharmaceutical company InMed Pharmaceuticals (INM [https://seekingalpha.com/symbol/INM]) added ~170% in the premarket on Tuesday after announcing an all-stock merger agreement with migrai…
(RTTNews) - InMed Pharmaceuticals (INM) has entered into a definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merg…
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates target…
NEW YORK, NY / ACCESS Newswire / March 18, 2026 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day March Small-Cap Virtual Investor Conference taking place Wedne…
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investors,…
* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20298167-inmed-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update] (INM [https://seekingalpha.com/symbol/INM]): Q1 GAAP EPS of -$0.44. * As of…
* InMed Pharmaceuticals press release [https://seekingalpha.com/pr/20241081-inmed-pharmaceuticals-reports-full-year-fiscal-2025-financial-results-and-provides-business] (NASDAQ:INM [https://seekingalpha.com/symbol/INM]): FY GAAP EPS of -$8…
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum, held September 18th are now ava…
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ…
NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-host…
* InMed Pharmaceuticals (NASDAQ:INM [https://seekingalpha.com/symbol/INM]) has filed a prospectus for the resale of up to 3.90M common shares by a selling shareholder and its permitted transferees. * The offering includes 1.95M shares from…
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo…
* InMed Pharmaceuticals (NASDAQ:INM [https://seekingalpha.com/symbol/INM]) has entered into definitive agreements for the issuance and sale of 1.95M of its common shares and short-term preferred investment options to purchase up to an aggr…
VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ:INM), a micro-cap pharmaceutical company with a market capitalization of approximately $3 million, announced Tuesday that its drug candidate INM-901 significantly reduced inflammation markers…
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates fo…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference seri…
Virtual Investor Conferences Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference…
Emerging Growth MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identi…
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 51st Emerging Growth Conference on March 8, 2023. The Emerging Growth Conference identifies companies i…
Closed calendar year 2022 with strong cash position of $11.5 millionApproaches completion of enrollment for Ph 2 clinical trial in EBAdvances research using rare cannabinoids in treating glaucoma and neurodegenerative diseases such as Alzh…
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid…
Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023Progress preclinical research in glaucoma in preparation for human trialsAdvance research using rare cannabinoids in treating neurodegenerative diseases such as…
VANCOUVER, British Columbia, Dec. 15, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid…
VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid…
Drug approvals and other regulatory news are in focus in the biotech sector. Collaboration deals were also in the spotlight during the week. Recap of the Week’s Most Important Stories: CytomX Soars on Regeneron Deal: Shares of CytomX Thera…
VANCOUVER, British Columbia, Nov. 21, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid…
VANCOUVER, British Columbia, Nov. 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid…